Keytruda Adds To Women’s Oncology Lead With Endometrial Cancer Data
Executive Summary
Published data showed Merck’s PD-1 inhibitor combined with Eisai’s Lenvima improved survival in the all-comer population of previously treated endometrial carcinoma.